207 related articles for article (PubMed ID: 10760047)
1. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.
Ying C; De Clercq E; Nicholson W; Furman P; Neyts J
J Viral Hepat; 2000 Mar; 7(2):161-5. PubMed ID: 10760047
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.
Chin R; Shaw T; Torresi J; Sozzi V; Trautwein C; Bock T; Manns M; Isom H; Furman P; Locarnini S
Antimicrob Agents Chemother; 2001 Sep; 45(9):2495-501. PubMed ID: 11502520
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture.
Ying C; De Clercq E; Neyts J
J Viral Hepat; 2000 Jan; 7(1):79-83. PubMed ID: 10718947
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
Seignères B; Pichoud C; Martin P; Furman P; Trépo C; Zoulim F
Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
Fu L; Liu SH; Cheng YC
Biochem Pharmacol; 1999 Jun; 57(12):1351-9. PubMed ID: 10353255
[TBL] [Abstract][Full Text] [Related]
7. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus.
Ying C; De Clercq E; Neyts J
Antiviral Res; 2000 Nov; 48(2):117-24. PubMed ID: 11114413
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
Ono-Nita SK; Kato N; Shiratori Y; Lan KH; Yoshida H; Carrilho FJ; Omata M
J Clin Invest; 1999 Jun; 103(12):1635-40. PubMed ID: 10377169
[TBL] [Abstract][Full Text] [Related]
10. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
[TBL] [Abstract][Full Text] [Related]
11. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir.
Shaw T; Mok SS; Locarnini SA
Hepatology; 1996 Nov; 24(5):996-1002. PubMed ID: 8903366
[TBL] [Abstract][Full Text] [Related]
13. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Leemans WF; Janssen HL; Niesters HG; de Man RA
J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
[TBL] [Abstract][Full Text] [Related]
16. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
Zhang Y; Zhang Y; Kang Y; Wang J; Liu H; Zhu H; Qin Y; Mao R; Lin X; Lu M; Zhang J
J Virol Methods; 2014 Jun; 201():51-6. PubMed ID: 24583110
[TBL] [Abstract][Full Text] [Related]
17. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.
Fu L; Cheng YC
Antimicrob Agents Chemother; 2000 Dec; 44(12):3402-7. PubMed ID: 11083647
[TBL] [Abstract][Full Text] [Related]
18. [Tetracycline-inducible replications of wild-type and an adefovir-dipivoxil-resistant hepatitis B virus in human liver cells].
Wang JH; Wang XY; Fei R; Zhang HY; Wei L
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Apr; 50(4):351-6. PubMed ID: 27029368
[TBL] [Abstract][Full Text] [Related]
19. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
[TBL] [Abstract][Full Text] [Related]
20. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.
Seifer M; Patty A; Serra I; Li B; Standring DN
Antiviral Res; 2009 Feb; 81(2):147-55. PubMed ID: 19028525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]